Sobi inks new distribution agreement for Ammonul

21 February 2017

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) says it has entered into a three-year agreement with Valeant Pharmaceuticals Ireland, a unit of Canada’s Valeant Pharmaceuticals International (TSX: VRX) for the distribution of Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East and North Africa.

The new agreement replaces the current distribution agreement with Valeant Pharmaceuticals North America for the same territory. Under the new agreement, Sobi will have exclusive rights and license for sales and distribution of Ammonul in Europe, the Middle East and North Africa until December 31, 2019 for named patient use (NPU) programs.

“We are very pleased to extend our long-term partnership with Valeant to continue to provide access to Ammonul in the territory,” says Alan Raffensperger, chief operating officer at Sobi, adding: “This agreement complements Sobi’s portfolio within the area of Urea Cycle Disorders and creates a wider range of treatment alternatives for patients suffering from these rare conditions”.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK